BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Mackelenbergh MG, Stroes CI, Spijker R, van Eijck CHJ, Wilmink JW, Bijlsma MF, van Laarhoven HWM. Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;11. [PMID: 31035512 DOI: 10.3390/cancers11050588] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Martínez-bosch N, Navarro P. Galectins in the Tumor Microenvironment: Focus on Galectin-1. In: Birbrair A, editor. Tumor Microenvironment. Cham: Springer International Publishing; 2020. pp. 17-38. [DOI: 10.1007/978-3-030-43093-1_2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Lodestijn SC, van Neerven SM, Vermeulen L, Bijlsma MF. Stem Cells in the Exocrine Pancreas during Homeostasis, Injury, and Cancer. Cancers (Basel) 2021;13:3295. [PMID: 34209288 DOI: 10.3390/cancers13133295] [Reference Citation Analysis]
3 Polani F, Grierson PM, Lim KH. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. World J Gastroenterol 2021; 27(18): 2105-2121 [PMID: 34025067 DOI: 10.3748/wjg.v27.i18.2105] [Reference Citation Analysis]
4 Liot S, Balas J, Aubert A, Prigent L, Mercier-Gouy P, Verrier B, Bertolino P, Hennino A, Valcourt U, Lambert E. Stroma Involvement in Pancreatic Ductal Adenocarcinoma: An Overview Focusing on Extracellular Matrix Proteins. Front Immunol 2021;12:612271. [PMID: 33889150 DOI: 10.3389/fimmu.2021.612271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Lai E, Puzzoni M, Ziranu P, Pretta A, Impera V, Mariani S, Liscia N, Soro P, Musio F, Persano M, Donisi C, Tolu S, Balconi F, Pireddu A, Demurtas L, Pusceddu V, Camera S, Sclafani F, Scartozzi M. New therapeutic targets in pancreatic cancer. Cancer Treat Rev 2019;81:101926. [PMID: 31739115 DOI: 10.1016/j.ctrv.2019.101926] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
6 Hennigan JN, Lynch MD. The past, present, and future of enzyme-based therapies. Drug Discov Today 2021:S1359-6446(21)00393-7. [PMID: 34537332 DOI: 10.1016/j.drudis.2021.09.004] [Reference Citation Analysis]
7 Edwards P, Kang BW, Chau I. Targeting the Stroma in the Management of Pancreatic Cancer. Front Oncol 2021;11:691185. [PMID: 34336679 DOI: 10.3389/fonc.2021.691185] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Sperb N, Tsesmelis M, Wirth T. Crosstalk between Tumor and Stromal Cells in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2020;21:E5486. [PMID: 32752017 DOI: 10.3390/ijms21155486] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
9 Beola L, Grazú V, Fernández-Afonso Y, Fratila RM, de Las Heras M, de la Fuente JM, Gutiérrez L, Asín L. Critical Parameters to Improve Pancreatic Cancer Treatment Using Magnetic Hyperthermia: Field Conditions, Immune Response, and Particle Biodistribution. ACS Appl Mater Interfaces 2021;13:12982-96. [PMID: 33709682 DOI: 10.1021/acsami.1c02338] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ; HALO 109-301 Investigators. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol 2020;38:3185-94. [PMID: 32706635 DOI: 10.1200/JCO.20.00590] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 25.0] [Reference Citation Analysis]
11 Abrams SL, Akula SM, Meher AK, Steelman LS, Gizak A, Duda P, Rakus D, Martelli AM, Ratti S, Cocco L, Montalto G, Cervello M, Ruvolo P, Libra M, Falzone L, Candido S, McCubrey JA. GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Cells 2021;10:816. [PMID: 33917370 DOI: 10.3390/cells10040816] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Lodestijn SC, Miedema DM, Lenos KJ, Nijman LE, Belt SC, El Makrini K, Lecca MC, Waasdorp C, van den Bosch T, Bijlsma MF, Vermeulen L. Marker-free lineage tracing reveals an environment-instructed clonogenic hierarchy in pancreatic cancer. Cell Rep 2021;37:109852. [PMID: 34686335 DOI: 10.1016/j.celrep.2021.109852] [Reference Citation Analysis]
13 Grapa CM, Mocan L, Crisan D, Florea M, Mocan T. Biomarkers in Pancreatic Cancer as Analytic Targets for Nanomediated Imaging and Therapy. Materials (Basel) 2021;14:3083. [PMID: 34199998 DOI: 10.3390/ma14113083] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Mayer P, Jiang Y, Kuder TA, Bergmann F, Khristenko E, Steinle V, Kaiser J, Hackert T, Kauczor HU, Klauß M, Gaida MM. Diffusion Kurtosis Imaging-A Superior Approach to Assess Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2020;12:E1656. [PMID: 32580519 DOI: 10.3390/cancers12061656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Silke J, O'Reilly LA. NF-κB and Pancreatic Cancer; Chapter and Verse. Cancers (Basel) 2021;13:4510. [PMID: 34572737 DOI: 10.3390/cancers13184510] [Reference Citation Analysis]
16 Nandi T, Pradyuth S, Singh AK, Chitkara D, Mittal A. Therapeutic agents for targeting desmoplasia: current status and emerging trends. Drug Discovery Today 2020;25:2046-55. [DOI: 10.1016/j.drudis.2020.09.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Alzhrani R, Alsaab HO, Vanamal K, Bhise K, Tatiparti K, Barari A, Sau S, Iyer AK. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes. Adv Ther (Weinh) 2021;4:2000262. [PMID: 34212073 DOI: 10.1002/adtp.202000262] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Shen J, Sun C, Wang Z, Chu Z, Liu C, Xu X, Xia M, Zhao M, Wang C. Sequential receptor-mediated mixed-charge nanomedicine to target pancreatic cancer, inducing immunogenic cell death and reshaping the tumor microenvironment. Int J Pharm 2021;601:120553. [PMID: 33794325 DOI: 10.1016/j.ijpharm.2021.120553] [Reference Citation Analysis]
19 Li Y, Al Hallak MN, Philip PA, Azmi AS, Mohammad RM. Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. Cancers (Basel) 2021;13:4161. [PMID: 34439315 DOI: 10.3390/cancers13164161] [Reference Citation Analysis]
20 Vincent P, Bruza P, Palisoul SM, Gunn JR, Samkoe KS, Hoopes PJ, Hasan T, Pogue BW. Visualization and quantification of pancreatic tumor stroma in fresh tissue via ultraviolet surface excitation. J Biomed Opt 2021;26. [PMID: 33423407 DOI: 10.1117/1.JBO.26.1.016002] [Reference Citation Analysis]
21 Lohse I, Brothers SP. Pathogenesis and Treatment of Pancreatic Cancer Related Pain. Anticancer Res 2020;40:1789-96. [PMID: 32234867 DOI: 10.21873/anticanres.14133] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
22 Steins A, van Mackelenbergh MG, van der Zalm AP, Klaassen R, Serrels B, Goris SG, Kocher HM, Waasdorp C, de Jong JH, Tekin C, Besselink MG, Busch OR, van de Vijver MJ, Verheij J, Dijk F, van Tienhoven G, Wilmink JW, Medema JP, van Laarhoven HW, Bijlsma MF. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. EMBO Rep 2020;21:e48780. [PMID: 32173982 DOI: 10.15252/embr.201948780] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]